Gallbladder melanoma

disease
On this page

Also known as gall bladder melanomagall bladder melanoma (disease)gallbladder malignant melanomamalignant melanoma of gallbladdermalignant melanoma of the gallbladdermelanoma (disease) of gall bladdermelanoma of gallbladdermelanoma of the gallbladder

Summary

Gallbladder melanoma (MONDO:0004484) is a cancer and 1 clinical trial. Top therapeutic interventions include cabozantinib. A subtype of gallbladder cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namegallbladder melanoma
Mondo IDMONDO:0004484
DOIDDOID:8167
NCITC5735
UMLSC1333749
MedGen232225
GARD0024030
Anatomy (UBERON)UBERON:0002110
Is cancer (heuristic)yes

Also known as: gall bladder melanoma · gall bladder melanoma (disease) · gallbladder malignant melanoma · gallbladder melanoma · malignant melanoma of gallbladder · malignant melanoma of the gallbladder · melanoma (disease) of gall bladder · melanoma of gallbladder · melanoma of the gallbladder

Disease family

This is a subtype of gallbladder cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderdigestive system cancergallbladder cancergallbladder melanoma

Related subtypes (4): gallbladder sarcoma, gallbladder carcinoma, neurofibroma of gallbladder, gallbladder lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05111574PHASE2RECRUITINGUsing Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CABOZANTINIB43